nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—CYP1A2—Carmustine—melanoma	0.15	0.328	CbGbCtD
Duloxetine—CYP1A2—Vemurafenib—melanoma	0.118	0.259	CbGbCtD
Duloxetine—CYP2D6—Vemurafenib—melanoma	0.0975	0.214	CbGbCtD
Duloxetine—CYP1A2—Dacarbazine—melanoma	0.0907	0.199	CbGbCtD
Duloxetine—Mediastinal disorder—Temozolomide—melanoma	0.000568	0.0018	CcSEcCtD
Duloxetine—Erythema—Carmustine—melanoma	0.000567	0.0018	CcSEcCtD
Duloxetine—Malnutrition—Carmustine—melanoma	0.000567	0.0018	CcSEcCtD
Duloxetine—Cough—Bleomycin—melanoma	0.000567	0.00179	CcSEcCtD
Duloxetine—Chills—Temozolomide—melanoma	0.000565	0.00179	CcSEcCtD
Duloxetine—Dehydration—Docetaxel—melanoma	0.000563	0.00178	CcSEcCtD
Duloxetine—Ill-defined disorder—Dactinomycin—melanoma	0.000563	0.00178	CcSEcCtD
Duloxetine—Anaemia—Dactinomycin—melanoma	0.00056	0.00177	CcSEcCtD
Duloxetine—Liver function test abnormal—Docetaxel—melanoma	0.000559	0.00177	CcSEcCtD
Duloxetine—Vomiting—Vemurafenib—melanoma	0.000557	0.00176	CcSEcCtD
Duloxetine—Alopecia—Temozolomide—melanoma	0.000557	0.00176	CcSEcCtD
Duloxetine—Myalgia—Bleomycin—melanoma	0.000553	0.00175	CcSEcCtD
Duloxetine—Chest pain—Bleomycin—melanoma	0.000553	0.00175	CcSEcCtD
Duloxetine—Abdominal pain upper—Docetaxel—melanoma	0.000553	0.00175	CcSEcCtD
Duloxetine—Orthostatic hypotension—Docetaxel—melanoma	0.000553	0.00175	CcSEcCtD
Duloxetine—Rash—Vemurafenib—melanoma	0.000552	0.00175	CcSEcCtD
Duloxetine—Mental disorder—Temozolomide—melanoma	0.000552	0.00175	CcSEcCtD
Duloxetine—Dermatitis—Vemurafenib—melanoma	0.000552	0.00175	CcSEcCtD
Duloxetine—Back pain—Carmustine—melanoma	0.000549	0.00174	CcSEcCtD
Duloxetine—Headache—Vemurafenib—melanoma	0.000549	0.00174	CcSEcCtD
Duloxetine—Malnutrition—Temozolomide—melanoma	0.000548	0.00173	CcSEcCtD
Duloxetine—Erythema—Temozolomide—melanoma	0.000548	0.00173	CcSEcCtD
Duloxetine—Breast disorder—Docetaxel—melanoma	0.000547	0.00173	CcSEcCtD
Duloxetine—Discomfort—Bleomycin—melanoma	0.000547	0.00173	CcSEcCtD
Duloxetine—Malaise—Dactinomycin—melanoma	0.000547	0.00173	CcSEcCtD
Duloxetine—Cramp muscle—Docetaxel—melanoma	0.000545	0.00173	CcSEcCtD
Duloxetine—Aspartate aminotransferase increased—Docetaxel—melanoma	0.000545	0.00173	CcSEcCtD
Duloxetine—Leukopenia—Dactinomycin—melanoma	0.000543	0.00172	CcSEcCtD
Duloxetine—Nasopharyngitis—Docetaxel—melanoma	0.000542	0.00171	CcSEcCtD
Duloxetine—Dysgeusia—Temozolomide—melanoma	0.000537	0.0017	CcSEcCtD
Duloxetine—Confusional state—Bleomycin—melanoma	0.000535	0.00169	CcSEcCtD
Duloxetine—Vision blurred—Carmustine—melanoma	0.000535	0.00169	CcSEcCtD
Duloxetine—Alanine aminotransferase increased—Docetaxel—melanoma	0.000534	0.00169	CcSEcCtD
Duloxetine—Tremor—Carmustine—melanoma	0.000532	0.00168	CcSEcCtD
Duloxetine—Anaphylactic shock—Bleomycin—melanoma	0.000531	0.00168	CcSEcCtD
Duloxetine—Oedema—Bleomycin—melanoma	0.000531	0.00168	CcSEcCtD
Duloxetine—Back pain—Temozolomide—melanoma	0.00053	0.00168	CcSEcCtD
Duloxetine—Infection—Bleomycin—melanoma	0.000527	0.00167	CcSEcCtD
Duloxetine—Anaemia—Carmustine—melanoma	0.000525	0.00166	CcSEcCtD
Duloxetine—Dysphagia—Docetaxel—melanoma	0.000523	0.00166	CcSEcCtD
Duloxetine—Agitation—Carmustine—melanoma	0.000522	0.00165	CcSEcCtD
Duloxetine—Nausea—Vemurafenib—melanoma	0.00052	0.00165	CcSEcCtD
Duloxetine—Thrombocytopenia—Bleomycin—melanoma	0.00052	0.00164	CcSEcCtD
Duloxetine—Vision blurred—Temozolomide—melanoma	0.000517	0.00163	CcSEcCtD
Duloxetine—Myalgia—Dactinomycin—melanoma	0.000516	0.00163	CcSEcCtD
Duloxetine—Tremor—Temozolomide—melanoma	0.000514	0.00163	CcSEcCtD
Duloxetine—Discomfort—Dactinomycin—melanoma	0.00051	0.00161	CcSEcCtD
Duloxetine—Ill-defined disorder—Temozolomide—melanoma	0.000509	0.00161	CcSEcCtD
Duloxetine—Leukopenia—Carmustine—melanoma	0.000508	0.00161	CcSEcCtD
Duloxetine—Anaemia—Temozolomide—melanoma	0.000507	0.0016	CcSEcCtD
Duloxetine—Anorexia—Bleomycin—melanoma	0.000506	0.0016	CcSEcCtD
Duloxetine—Agitation—Temozolomide—melanoma	0.000504	0.00159	CcSEcCtD
Duloxetine—Angioedema—Temozolomide—melanoma	0.000501	0.00159	CcSEcCtD
Duloxetine—Oedema—Dactinomycin—melanoma	0.000495	0.00157	CcSEcCtD
Duloxetine—Malaise—Temozolomide—melanoma	0.000495	0.00156	CcSEcCtD
Duloxetine—Vertigo—Temozolomide—melanoma	0.000493	0.00156	CcSEcCtD
Duloxetine—Convulsion—Carmustine—melanoma	0.000492	0.00156	CcSEcCtD
Duloxetine—Infection—Dactinomycin—melanoma	0.000492	0.00156	CcSEcCtD
Duloxetine—Leukopenia—Temozolomide—melanoma	0.000491	0.00155	CcSEcCtD
Duloxetine—Hypertension—Carmustine—melanoma	0.00049	0.00155	CcSEcCtD
Duloxetine—Palpitations—Temozolomide—melanoma	0.000485	0.00153	CcSEcCtD
Duloxetine—Thrombocytopenia—Dactinomycin—melanoma	0.000485	0.00153	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Bleomycin—melanoma	0.000483	0.00153	CcSEcCtD
Duloxetine—Myalgia—Carmustine—melanoma	0.000483	0.00153	CcSEcCtD
Duloxetine—Chest pain—Carmustine—melanoma	0.000483	0.00153	CcSEcCtD
Duloxetine—Anxiety—Carmustine—melanoma	0.000481	0.00152	CcSEcCtD
Duloxetine—Cough—Temozolomide—melanoma	0.000479	0.00151	CcSEcCtD
Duloxetine—Paraesthesia—Bleomycin—melanoma	0.000476	0.00151	CcSEcCtD
Duloxetine—Weight increased—Docetaxel—melanoma	0.000476	0.00151	CcSEcCtD
Duloxetine—Convulsion—Temozolomide—melanoma	0.000475	0.0015	CcSEcCtD
Duloxetine—Weight decreased—Docetaxel—melanoma	0.000474	0.0015	CcSEcCtD
Duloxetine—Hypertension—Temozolomide—melanoma	0.000473	0.0015	CcSEcCtD
Duloxetine—Anorexia—Dactinomycin—melanoma	0.000472	0.00149	CcSEcCtD
Duloxetine—Confusional state—Carmustine—melanoma	0.000467	0.00148	CcSEcCtD
Duloxetine—Arthralgia—Temozolomide—melanoma	0.000467	0.00148	CcSEcCtD
Duloxetine—Myalgia—Temozolomide—melanoma	0.000467	0.00148	CcSEcCtD
Duloxetine—Infestation NOS—Docetaxel—melanoma	0.000467	0.00148	CcSEcCtD
Duloxetine—Infestation—Docetaxel—melanoma	0.000467	0.00148	CcSEcCtD
Duloxetine—Anxiety—Temozolomide—melanoma	0.000465	0.00147	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000464	0.00147	CcSEcCtD
Duloxetine—Oedema—Carmustine—melanoma	0.000463	0.00147	CcSEcCtD
Duloxetine—Stevens-Johnson syndrome—Docetaxel—melanoma	0.000463	0.00146	CcSEcCtD
Duloxetine—Discomfort—Temozolomide—melanoma	0.000461	0.00146	CcSEcCtD
Duloxetine—Decreased appetite—Bleomycin—melanoma	0.000461	0.00146	CcSEcCtD
Duloxetine—Infection—Carmustine—melanoma	0.00046	0.00146	CcSEcCtD
Duloxetine—Acute coronary syndrome—Docetaxel—melanoma	0.00046	0.00146	CcSEcCtD
Duloxetine—Renal failure—Docetaxel—melanoma	0.000459	0.00145	CcSEcCtD
Duloxetine—Myocardial infarction—Docetaxel—melanoma	0.000457	0.00145	CcSEcCtD
Duloxetine—Dry mouth—Temozolomide—melanoma	0.000457	0.00144	CcSEcCtD
Duloxetine—Stomatitis—Docetaxel—melanoma	0.000455	0.00144	CcSEcCtD
Duloxetine—Jaundice—Docetaxel—melanoma	0.000455	0.00144	CcSEcCtD
Duloxetine—Pain—Bleomycin—melanoma	0.000454	0.00144	CcSEcCtD
Duloxetine—Conjunctivitis—Docetaxel—melanoma	0.000454	0.00143	CcSEcCtD
Duloxetine—Thrombocytopenia—Carmustine—melanoma	0.000453	0.00143	CcSEcCtD
Duloxetine—Tachycardia—Carmustine—melanoma	0.000452	0.00143	CcSEcCtD
Duloxetine—Confusional state—Temozolomide—melanoma	0.000451	0.00143	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000451	0.00143	CcSEcCtD
Duloxetine—Oedema—Temozolomide—melanoma	0.000448	0.00142	CcSEcCtD
Duloxetine—Anaphylactic shock—Temozolomide—melanoma	0.000448	0.00142	CcSEcCtD
Duloxetine—Infection—Temozolomide—melanoma	0.000445	0.00141	CcSEcCtD
Duloxetine—Anorexia—Carmustine—melanoma	0.000441	0.0014	CcSEcCtD
Duloxetine—Hepatobiliary disease—Docetaxel—melanoma	0.000441	0.0014	CcSEcCtD
Duloxetine—Epistaxis—Docetaxel—melanoma	0.00044	0.00139	CcSEcCtD
Duloxetine—Nervous system disorder—Temozolomide—melanoma	0.000439	0.00139	CcSEcCtD
Duloxetine—Thrombocytopenia—Temozolomide—melanoma	0.000438	0.00139	CcSEcCtD
Duloxetine—Feeling abnormal—Bleomycin—melanoma	0.000437	0.00138	CcSEcCtD
Duloxetine—Skin disorder—Temozolomide—melanoma	0.000435	0.00138	CcSEcCtD
Duloxetine—Hyperhidrosis—Temozolomide—melanoma	0.000433	0.00137	CcSEcCtD
Duloxetine—Decreased appetite—Dactinomycin—melanoma	0.00043	0.00136	CcSEcCtD
Duloxetine—Fatigue—Dactinomycin—melanoma	0.000427	0.00135	CcSEcCtD
Duloxetine—Anorexia—Temozolomide—melanoma	0.000427	0.00135	CcSEcCtD
Duloxetine—Pain—Dactinomycin—melanoma	0.000423	0.00134	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Carmustine—melanoma	0.000422	0.00133	CcSEcCtD
Duloxetine—Urticaria—Bleomycin—melanoma	0.000422	0.00133	CcSEcCtD
Duloxetine—Haemoglobin—Docetaxel—melanoma	0.000421	0.00133	CcSEcCtD
Duloxetine—Body temperature increased—Bleomycin—melanoma	0.000419	0.00133	CcSEcCtD
Duloxetine—Haemorrhage—Docetaxel—melanoma	0.000419	0.00133	CcSEcCtD
Duloxetine—Hepatitis—Docetaxel—melanoma	0.000419	0.00133	CcSEcCtD
Duloxetine—Insomnia—Carmustine—melanoma	0.000419	0.00133	CcSEcCtD
Duloxetine—Hypoaesthesia—Docetaxel—melanoma	0.000417	0.00132	CcSEcCtD
Duloxetine—Paraesthesia—Carmustine—melanoma	0.000416	0.00132	CcSEcCtD
Duloxetine—Pharyngitis—Docetaxel—melanoma	0.000416	0.00132	CcSEcCtD
Duloxetine—Urinary tract disorder—Docetaxel—melanoma	0.000414	0.00131	CcSEcCtD
Duloxetine—Oedema peripheral—Docetaxel—melanoma	0.000413	0.00131	CcSEcCtD
Duloxetine—Somnolence—Carmustine—melanoma	0.000412	0.0013	CcSEcCtD
Duloxetine—Connective tissue disorder—Docetaxel—melanoma	0.000412	0.0013	CcSEcCtD
Duloxetine—Urethral disorder—Docetaxel—melanoma	0.000411	0.0013	CcSEcCtD
Duloxetine—Feeling abnormal—Dactinomycin—melanoma	0.000408	0.00129	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Temozolomide—melanoma	0.000408	0.00129	CcSEcCtD
Duloxetine—Insomnia—Temozolomide—melanoma	0.000405	0.00128	CcSEcCtD
Duloxetine—Gastrointestinal pain—Dactinomycin—melanoma	0.000405	0.00128	CcSEcCtD
Duloxetine—Visual impairment—Docetaxel—melanoma	0.000404	0.00128	CcSEcCtD
Duloxetine—Decreased appetite—Carmustine—melanoma	0.000403	0.00127	CcSEcCtD
Duloxetine—Paraesthesia—Temozolomide—melanoma	0.000402	0.00127	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Carmustine—melanoma	0.0004	0.00126	CcSEcCtD
Duloxetine—Somnolence—Temozolomide—melanoma	0.000398	0.00126	CcSEcCtD
Duloxetine—Erythema multiforme—Docetaxel—melanoma	0.000396	0.00125	CcSEcCtD
Duloxetine—Pain—Carmustine—melanoma	0.000396	0.00125	CcSEcCtD
Duloxetine—Constipation—Carmustine—melanoma	0.000396	0.00125	CcSEcCtD
Duloxetine—Dyspepsia—Temozolomide—melanoma	0.000394	0.00125	CcSEcCtD
Duloxetine—Eye disorder—Docetaxel—melanoma	0.000392	0.00124	CcSEcCtD
Duloxetine—Abdominal pain—Dactinomycin—melanoma	0.000391	0.00124	CcSEcCtD
Duloxetine—Body temperature increased—Dactinomycin—melanoma	0.000391	0.00124	CcSEcCtD
Duloxetine—Hypersensitivity—Bleomycin—melanoma	0.000391	0.00124	CcSEcCtD
Duloxetine—Decreased appetite—Temozolomide—melanoma	0.000389	0.00123	CcSEcCtD
Duloxetine—Cardiac disorder—Docetaxel—melanoma	0.000389	0.00123	CcSEcCtD
Duloxetine—Flushing—Docetaxel—melanoma	0.000389	0.00123	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Temozolomide—melanoma	0.000386	0.00122	CcSEcCtD
Duloxetine—Fatigue—Temozolomide—melanoma	0.000386	0.00122	CcSEcCtD
Duloxetine—Pain—Temozolomide—melanoma	0.000383	0.00121	CcSEcCtD
Duloxetine—Constipation—Temozolomide—melanoma	0.000383	0.00121	CcSEcCtD
Duloxetine—Feeling abnormal—Carmustine—melanoma	0.000382	0.00121	CcSEcCtD
Duloxetine—Asthenia—Bleomycin—melanoma	0.000381	0.0012	CcSEcCtD
Duloxetine—Angiopathy—Docetaxel—melanoma	0.00038	0.0012	CcSEcCtD
Duloxetine—Gastrointestinal pain—Carmustine—melanoma	0.000379	0.0012	CcSEcCtD
Duloxetine—Immune system disorder—Docetaxel—melanoma	0.000378	0.0012	CcSEcCtD
Duloxetine—Mediastinal disorder—Docetaxel—melanoma	0.000378	0.00119	CcSEcCtD
Duloxetine—Chills—Docetaxel—melanoma	0.000376	0.00119	CcSEcCtD
Duloxetine—Pruritus—Bleomycin—melanoma	0.000375	0.00119	CcSEcCtD
Duloxetine—Arrhythmia—Docetaxel—melanoma	0.000374	0.00118	CcSEcCtD
Duloxetine—Alopecia—Docetaxel—melanoma	0.00037	0.00117	CcSEcCtD
Duloxetine—Feeling abnormal—Temozolomide—melanoma	0.000369	0.00117	CcSEcCtD
Duloxetine—Mental disorder—Docetaxel—melanoma	0.000367	0.00116	CcSEcCtD
Duloxetine—Abdominal pain—Carmustine—melanoma	0.000366	0.00116	CcSEcCtD
Duloxetine—Body temperature increased—Carmustine—melanoma	0.000366	0.00116	CcSEcCtD
Duloxetine—Gastrointestinal pain—Temozolomide—melanoma	0.000366	0.00116	CcSEcCtD
Duloxetine—Malnutrition—Docetaxel—melanoma	0.000365	0.00115	CcSEcCtD
Duloxetine—Erythema—Docetaxel—melanoma	0.000365	0.00115	CcSEcCtD
Duloxetine—Hypersensitivity—Dactinomycin—melanoma	0.000365	0.00115	CcSEcCtD
Duloxetine—Dysgeusia—Docetaxel—melanoma	0.000357	0.00113	CcSEcCtD
Duloxetine—Urticaria—Temozolomide—melanoma	0.000356	0.00112	CcSEcCtD
Duloxetine—Asthenia—Dactinomycin—melanoma	0.000355	0.00112	CcSEcCtD
Duloxetine—Abdominal pain—Temozolomide—melanoma	0.000354	0.00112	CcSEcCtD
Duloxetine—Body temperature increased—Temozolomide—melanoma	0.000354	0.00112	CcSEcCtD
Duloxetine—Back pain—Docetaxel—melanoma	0.000353	0.00112	CcSEcCtD
Duloxetine—Muscle spasms—Docetaxel—melanoma	0.000351	0.00111	CcSEcCtD
Duloxetine—Hypersensitivity—Carmustine—melanoma	0.000341	0.00108	CcSEcCtD
Duloxetine—Diarrhoea—Dactinomycin—melanoma	0.000339	0.00107	CcSEcCtD
Duloxetine—Vomiting—Bleomycin—melanoma	0.000337	0.00107	CcSEcCtD
Duloxetine—Anaemia—Docetaxel—melanoma	0.000337	0.00107	CcSEcCtD
Duloxetine—Rash—Bleomycin—melanoma	0.000335	0.00106	CcSEcCtD
Duloxetine—Dermatitis—Bleomycin—melanoma	0.000334	0.00106	CcSEcCtD
Duloxetine—Asthenia—Carmustine—melanoma	0.000332	0.00105	CcSEcCtD
Duloxetine—Hypersensitivity—Temozolomide—melanoma	0.00033	0.00104	CcSEcCtD
Duloxetine—Syncope—Docetaxel—melanoma	0.000327	0.00103	CcSEcCtD
Duloxetine—Leukopenia—Docetaxel—melanoma	0.000326	0.00103	CcSEcCtD
Duloxetine—Palpitations—Docetaxel—melanoma	0.000322	0.00102	CcSEcCtD
Duloxetine—Asthenia—Temozolomide—melanoma	0.000321	0.00102	CcSEcCtD
Duloxetine—Loss of consciousness—Docetaxel—melanoma	0.000321	0.00101	CcSEcCtD
Duloxetine—Cough—Docetaxel—melanoma	0.000318	0.00101	CcSEcCtD
Duloxetine—Diarrhoea—Carmustine—melanoma	0.000317	0.001	CcSEcCtD
Duloxetine—Pruritus—Temozolomide—melanoma	0.000317	0.001	CcSEcCtD
Duloxetine—Convulsion—Docetaxel—melanoma	0.000316	0.001	CcSEcCtD
Duloxetine—Nausea—Bleomycin—melanoma	0.000315	0.000997	CcSEcCtD
Duloxetine—Hypertension—Docetaxel—melanoma	0.000315	0.000996	CcSEcCtD
Duloxetine—Vomiting—Dactinomycin—melanoma	0.000315	0.000995	CcSEcCtD
Duloxetine—Rash—Dactinomycin—melanoma	0.000312	0.000987	CcSEcCtD
Duloxetine—Chest pain—Docetaxel—melanoma	0.00031	0.000982	CcSEcCtD
Duloxetine—Myalgia—Docetaxel—melanoma	0.00031	0.000982	CcSEcCtD
Duloxetine—Arthralgia—Docetaxel—melanoma	0.00031	0.000982	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000308	0.000975	CcSEcCtD
Duloxetine—Dizziness—Carmustine—melanoma	0.000306	0.000969	CcSEcCtD
Duloxetine—Diarrhoea—Temozolomide—melanoma	0.000306	0.000969	CcSEcCtD
Duloxetine—Dry mouth—Docetaxel—melanoma	0.000304	0.000961	CcSEcCtD
Duloxetine—Confusional state—Docetaxel—melanoma	0.0003	0.000949	CcSEcCtD
Duloxetine—Anaphylactic shock—Docetaxel—melanoma	0.000298	0.000942	CcSEcCtD
Duloxetine—Oedema—Docetaxel—melanoma	0.000298	0.000942	CcSEcCtD
Duloxetine—Dizziness—Temozolomide—melanoma	0.000296	0.000936	CcSEcCtD
Duloxetine—Infection—Docetaxel—melanoma	0.000296	0.000935	CcSEcCtD
Duloxetine—Vomiting—Carmustine—melanoma	0.000294	0.000931	CcSEcCtD
Duloxetine—Nausea—Dactinomycin—melanoma	0.000294	0.00093	CcSEcCtD
Duloxetine—Shock—Docetaxel—melanoma	0.000293	0.000926	CcSEcCtD
Duloxetine—Rash—Carmustine—melanoma	0.000292	0.000924	CcSEcCtD
Duloxetine—Nervous system disorder—Docetaxel—melanoma	0.000292	0.000923	CcSEcCtD
Duloxetine—Dermatitis—Carmustine—melanoma	0.000292	0.000923	CcSEcCtD
Duloxetine—Thrombocytopenia—Docetaxel—melanoma	0.000291	0.000922	CcSEcCtD
Duloxetine—Tachycardia—Docetaxel—melanoma	0.00029	0.000919	CcSEcCtD
Duloxetine—Headache—Carmustine—melanoma	0.00029	0.000918	CcSEcCtD
Duloxetine—Skin disorder—Docetaxel—melanoma	0.000289	0.000915	CcSEcCtD
Duloxetine—Vomiting—Temozolomide—melanoma	0.000285	0.0009	CcSEcCtD
Duloxetine—Anorexia—Docetaxel—melanoma	0.000284	0.000897	CcSEcCtD
Duloxetine—Rash—Temozolomide—melanoma	0.000282	0.000893	CcSEcCtD
Duloxetine—Dermatitis—Temozolomide—melanoma	0.000282	0.000892	CcSEcCtD
Duloxetine—Headache—Temozolomide—melanoma	0.00028	0.000887	CcSEcCtD
Duloxetine—Nausea—Carmustine—melanoma	0.000275	0.00087	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Docetaxel—melanoma	0.000271	0.000858	CcSEcCtD
Duloxetine—Insomnia—Docetaxel—melanoma	0.000269	0.000852	CcSEcCtD
Duloxetine—Paraesthesia—Docetaxel—melanoma	0.000267	0.000845	CcSEcCtD
Duloxetine—Nausea—Temozolomide—melanoma	0.000266	0.000841	CcSEcCtD
Duloxetine—Somnolence—Docetaxel—melanoma	0.000265	0.000837	CcSEcCtD
Duloxetine—Dyspepsia—Docetaxel—melanoma	0.000262	0.000829	CcSEcCtD
Duloxetine—Decreased appetite—Docetaxel—melanoma	0.000259	0.000818	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Docetaxel—melanoma	0.000257	0.000813	CcSEcCtD
Duloxetine—Fatigue—Docetaxel—melanoma	0.000257	0.000812	CcSEcCtD
Duloxetine—Pain—Docetaxel—melanoma	0.000255	0.000805	CcSEcCtD
Duloxetine—Constipation—Docetaxel—melanoma	0.000255	0.000805	CcSEcCtD
Duloxetine—Feeling abnormal—Docetaxel—melanoma	0.000245	0.000776	CcSEcCtD
Duloxetine—Gastrointestinal pain—Docetaxel—melanoma	0.000243	0.00077	CcSEcCtD
Duloxetine—Abdominal pain—Docetaxel—melanoma	0.000235	0.000744	CcSEcCtD
Duloxetine—Body temperature increased—Docetaxel—melanoma	0.000235	0.000744	CcSEcCtD
Duloxetine—Hypersensitivity—Docetaxel—melanoma	0.000219	0.000694	CcSEcCtD
Duloxetine—Asthenia—Docetaxel—melanoma	0.000214	0.000676	CcSEcCtD
Duloxetine—Pruritus—Docetaxel—melanoma	0.000211	0.000666	CcSEcCtD
Duloxetine—Diarrhoea—Docetaxel—melanoma	0.000204	0.000644	CcSEcCtD
Duloxetine—Dizziness—Docetaxel—melanoma	0.000197	0.000623	CcSEcCtD
Duloxetine—Vomiting—Docetaxel—melanoma	0.000189	0.000599	CcSEcCtD
Duloxetine—Rash—Docetaxel—melanoma	0.000188	0.000594	CcSEcCtD
Duloxetine—Dermatitis—Docetaxel—melanoma	0.000187	0.000593	CcSEcCtD
Duloxetine—Headache—Docetaxel—melanoma	0.000186	0.00059	CcSEcCtD
Duloxetine—Nausea—Docetaxel—melanoma	0.000177	0.000559	CcSEcCtD
Duloxetine—Protriptyline—ABCB1—melanoma	7.72e-05	0.355	CrCbGaD
Duloxetine—Fluoxetine—ALB—melanoma	5.52e-05	0.254	CrCbGaD
Duloxetine—Fluoxetine—ABCB1—melanoma	5.27e-05	0.243	CrCbGaD
Duloxetine—Propranolol—ABCB1—melanoma	3.22e-05	0.148	CrCbGaD
Duloxetine—CYP2D6—Metabolism—VCAN—melanoma	2.3e-05	0.000101	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SYK—melanoma	2.26e-05	9.93e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ERBB4—melanoma	2.26e-05	9.91e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CB—melanoma	2.25e-05	9.89e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CD—melanoma	2.24e-05	9.85e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CDKN2B—melanoma	2.24e-05	9.83e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—FN1—melanoma	2.23e-05	9.82e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ITGAV—melanoma	2.22e-05	9.75e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKT3—melanoma	2.22e-05	9.75e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NGFR—melanoma	2.22e-05	9.75e-05	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—AKT1—melanoma	2.21e-05	9.72e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NOTCH1—melanoma	2.19e-05	9.61e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PLA2G6—melanoma	2.17e-05	9.53e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CD86—melanoma	2.16e-05	9.5e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CXCL8—melanoma	2.16e-05	9.5e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EDN1—melanoma	2.15e-05	9.43e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CD80—melanoma	2.14e-05	9.42e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—APC—melanoma	2.14e-05	9.4e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KIT—melanoma	2.14e-05	9.4e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CG—melanoma	2.14e-05	9.4e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—NRAS—melanoma	2.14e-05	9.4e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EGF—melanoma	2.11e-05	9.29e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FGF1—melanoma	2.1e-05	9.22e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CSF2—melanoma	2.1e-05	9.22e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—IL2—melanoma	2.07e-05	9.08e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SOCS1—melanoma	2.05e-05	9.02e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—E2F1—melanoma	2.05e-05	9.02e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—MAP2K1—melanoma	2.05e-05	9e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—S100B—melanoma	2.05e-05	9e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—MAPK3—melanoma	2.05e-05	9e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CB—melanoma	2.04e-05	8.98e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CD—melanoma	2.04e-05	8.94e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PDGFRA—melanoma	2.03e-05	8.93e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ITGB3—melanoma	2.01e-05	8.84e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PRKCA—melanoma	2.01e-05	8.84e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—BRAF—melanoma	2.01e-05	8.83e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SPP1—melanoma	1.97e-05	8.67e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAP2K2—melanoma	1.97e-05	8.64e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CXCL8—melanoma	1.96e-05	8.63e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ERBB4—melanoma	1.96e-05	8.61e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IGF1—melanoma	1.96e-05	8.61e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CB—melanoma	1.95e-05	8.59e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—MAPK1—melanoma	1.95e-05	8.56e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—VCAN—melanoma	1.95e-05	8.56e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—EGFR—melanoma	1.95e-05	8.56e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDKN2B—melanoma	1.94e-05	8.53e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP17A1—melanoma	1.94e-05	8.53e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAP2K1—melanoma	1.89e-05	8.32e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CD—melanoma	1.88e-05	8.26e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CD86—melanoma	1.88e-05	8.25e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CXCL8—melanoma	1.88e-05	8.25e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL2—melanoma	1.88e-05	8.24e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TERT—melanoma	1.87e-05	8.21e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RAC1—melanoma	1.86e-05	8.19e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EDN1—melanoma	1.86e-05	8.19e-05	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—PIK3CA—melanoma	1.86e-05	8.18e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	1.84e-05	8.11e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—KRAS—melanoma	1.84e-05	8.09e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GNA11—melanoma	1.83e-05	8.05e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CSF2—melanoma	1.82e-05	8e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FGF1—melanoma	1.82e-05	8e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—FGF2—melanoma	1.8e-05	7.91e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—IL2—melanoma	1.79e-05	7.88e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—FASN—melanoma	1.79e-05	7.88e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HIF1A—melanoma	1.79e-05	7.86e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—E2F1—melanoma	1.78e-05	7.83e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—melanoma	1.78e-05	7.82e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CB—melanoma	1.77e-05	7.8e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC5A5—melanoma	1.76e-05	7.75e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PDGFRA—melanoma	1.76e-05	7.75e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PRKCA—melanoma	1.75e-05	7.67e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ITGB3—melanoma	1.75e-05	7.67e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SPP1—melanoma	1.71e-05	7.53e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KDR—melanoma	1.71e-05	7.51e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAP2K2—melanoma	1.71e-05	7.5e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CXCL8—melanoma	1.7e-05	7.49e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GNAQ—melanoma	1.7e-05	7.49e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CD44—melanoma	1.7e-05	7.49e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PIK3CA—melanoma	1.69e-05	7.43e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MDM2—melanoma	1.68e-05	7.4e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ERBB2—melanoma	1.66e-05	7.3e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FN1—melanoma	1.65e-05	7.23e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP17A1—melanoma	1.64e-05	7.22e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CB—melanoma	1.64e-05	7.2e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP1B1—melanoma	1.63e-05	7.18e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL2—melanoma	1.63e-05	7.16e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TERT—melanoma	1.62e-05	7.13e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	1.62e-05	7.13e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RAC1—melanoma	1.62e-05	7.11e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NOTCH1—melanoma	1.61e-05	7.08e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—melanoma	1.6e-05	7.03e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CD80—melanoma	1.58e-05	6.93e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CG—melanoma	1.57e-05	6.92e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KIT—melanoma	1.57e-05	6.92e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APC—melanoma	1.57e-05	6.92e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—NRAS—melanoma	1.57e-05	6.92e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CXCL8—melanoma	1.57e-05	6.92e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—HRAS—melanoma	1.56e-05	6.88e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EGF—melanoma	1.56e-05	6.84e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GNA11—melanoma	1.55e-05	6.82e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HIF1A—melanoma	1.55e-05	6.82e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CDKN1B—melanoma	1.54e-05	6.76e-05	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AKT1—melanoma	1.52e-05	6.69e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—FASN—melanoma	1.52e-05	6.68e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—MAPK3—melanoma	1.51e-05	6.63e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CASP3—melanoma	1.51e-05	6.62e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL2—melanoma	1.5e-05	6.61e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL6—melanoma	1.5e-05	6.58e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC5A5—melanoma	1.49e-05	6.57e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KDR—melanoma	1.48e-05	6.52e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—BRAF—melanoma	1.48e-05	6.51e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCND1—melanoma	1.47e-05	6.45e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CTNNB1—melanoma	1.45e-05	6.38e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CD44—melanoma	1.44e-05	6.34e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GNAQ—melanoma	1.44e-05	6.34e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IGF1—melanoma	1.44e-05	6.34e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—MAPK1—melanoma	1.44e-05	6.31e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—EGFR—melanoma	1.43e-05	6.31e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FN1—melanoma	1.43e-05	6.28e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MMP9—melanoma	1.42e-05	6.26e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CDKN1A—melanoma	1.42e-05	6.24e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTEN—melanoma	1.42e-05	6.22e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	1.41e-05	6.21e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NFKB1—melanoma	1.41e-05	6.19e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—melanoma	1.4e-05	6.15e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOTCH1—melanoma	1.4e-05	6.15e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAP2K1—melanoma	1.39e-05	6.12e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CD—melanoma	1.38e-05	6.08e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP1B1—melanoma	1.38e-05	6.08e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AKT1—melanoma	1.38e-05	6.07e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CA—melanoma	1.37e-05	6.03e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CD80—melanoma	1.37e-05	6.02e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KIT—melanoma	1.37e-05	6.01e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APC—melanoma	1.37e-05	6.01e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CG—melanoma	1.37e-05	6.01e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—NRAS—melanoma	1.37e-05	6.01e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—KRAS—melanoma	1.36e-05	5.96e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EGF—melanoma	1.35e-05	5.94e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ABCB1—melanoma	1.35e-05	5.91e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FGF2—melanoma	1.33e-05	5.83e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—MAPK3—melanoma	1.31e-05	5.76e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—BRAF—melanoma	1.29e-05	5.65e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—VEGFA—melanoma	1.28e-05	5.62e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—STAT3—melanoma	1.27e-05	5.57e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NRAS—melanoma	1.26e-05	5.55e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IGF1—melanoma	1.25e-05	5.5e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—MAPK1—melanoma	1.25e-05	5.48e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—EGFR—melanoma	1.25e-05	5.48e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CA—melanoma	1.25e-05	5.47e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MDM2—melanoma	1.24e-05	5.45e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PRKCA—melanoma	1.24e-05	5.44e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ERCC2—melanoma	1.23e-05	5.4e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ERBB2—melanoma	1.22e-05	5.37e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.22e-05	5.37e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAP2K1—melanoma	1.21e-05	5.32e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAPK3—melanoma	1.21e-05	5.32e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CB—melanoma	1.21e-05	5.3e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CD—melanoma	1.2e-05	5.28e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CA—melanoma	1.19e-05	5.23e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—KRAS—melanoma	1.18e-05	5.17e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MYC—melanoma	1.18e-05	5.17e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCL8—melanoma	1.16e-05	5.1e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—HRAS—melanoma	1.15e-05	5.06e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MAPK1—melanoma	1.15e-05	5.06e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FGF2—melanoma	1.15e-05	5.06e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EGFR—melanoma	1.15e-05	5.06e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ABCB1—melanoma	1.14e-05	5.01e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CDKN1B—melanoma	1.13e-05	4.98e-05	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AKT1—melanoma	1.12e-05	4.92e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CASP3—melanoma	1.11e-05	4.88e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL2—melanoma	1.11e-05	4.87e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6—melanoma	1.1e-05	4.85e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KRAS—melanoma	1.09e-05	4.78e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CA—melanoma	1.08e-05	4.75e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCND1—melanoma	1.08e-05	4.75e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MDM2—melanoma	1.08e-05	4.73e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CTNNB1—melanoma	1.07e-05	4.7e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ERBB2—melanoma	1.06e-05	4.67e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MMP9—melanoma	1.05e-05	4.61e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PRKCA—melanoma	1.05e-05	4.61e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CB—melanoma	1.05e-05	4.61e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CDKN1A—melanoma	1.05e-05	4.59e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTEN—melanoma	1.04e-05	4.58e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ERCC2—melanoma	1.04e-05	4.57e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NFKB1—melanoma	1.04e-05	4.56e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AKT1—melanoma	1.02e-05	4.47e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCL8—melanoma	1.01e-05	4.43e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—HRAS—melanoma	1e-05	4.4e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CA—melanoma	9.99e-06	4.39e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDKN1B—melanoma	9.83e-06	4.32e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AKT1—melanoma	9.73e-06	4.28e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CG—melanoma	9.7e-06	4.26e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TP53—melanoma	9.66e-06	4.25e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CASP3—melanoma	9.64e-06	4.24e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL2—melanoma	9.62e-06	4.23e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6—melanoma	9.58e-06	4.21e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—VEGFA—melanoma	9.42e-06	4.14e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCND1—melanoma	9.38e-06	4.12e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPARG—melanoma	9.36e-06	4.11e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—STAT3—melanoma	9.33e-06	4.1e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NRAS—melanoma	9.3e-06	4.09e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CTNNB1—melanoma	9.29e-06	4.08e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HRAS—melanoma	9.24e-06	4.06e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MMP9—melanoma	9.11e-06	4e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDKN1A—melanoma	9.08e-06	3.99e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTEN—melanoma	9.06e-06	3.98e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NFKB1—melanoma	9.01e-06	3.96e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAPK3—melanoma	8.91e-06	3.92e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6—melanoma	8.85e-06	3.89e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AKT1—melanoma	8.83e-06	3.88e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MYC—melanoma	8.67e-06	3.81e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	8.62e-06	3.79e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CD—melanoma	8.52e-06	3.75e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MAPK1—melanoma	8.48e-06	3.73e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EGFR—melanoma	8.48e-06	3.73e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALB—melanoma	8.41e-06	3.7e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CG—melanoma	8.21e-06	3.61e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VEGFA—melanoma	8.18e-06	3.59e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKT1—melanoma	8.16e-06	3.59e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—STAT3—melanoma	8.1e-06	3.56e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NRAS—melanoma	8.08e-06	3.55e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KRAS—melanoma	8.01e-06	3.52e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPARG—melanoma	7.93e-06	3.48e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAPK3—melanoma	7.74e-06	3.4e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MYC—melanoma	7.53e-06	3.31e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CB—melanoma	7.43e-06	3.27e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MAPK1—melanoma	7.36e-06	3.24e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS2—melanoma	7.36e-06	3.24e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EGFR—melanoma	7.36e-06	3.23e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CA—melanoma	7.36e-06	3.23e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CD—melanoma	7.22e-06	3.17e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALB—melanoma	7.13e-06	3.13e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TP53—melanoma	7.12e-06	3.13e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KRAS—melanoma	6.95e-06	3.06e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HRAS—melanoma	6.81e-06	2.99e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6—melanoma	6.51e-06	2.86e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTEN—melanoma	6.42e-06	2.82e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CA—melanoma	6.39e-06	2.81e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CB—melanoma	6.29e-06	2.77e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS2—melanoma	6.24e-06	2.74e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TP53—melanoma	6.18e-06	2.72e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKT1—melanoma	6.01e-06	2.64e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HRAS—melanoma	5.91e-06	2.6e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6—melanoma	5.66e-06	2.49e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTEN—melanoma	5.44e-06	2.39e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKT1—melanoma	5.22e-06	2.29e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CA—melanoma	4.53e-06	1.99e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CA—melanoma	3.84e-06	1.69e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AKT1—melanoma	3.7e-06	1.63e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AKT1—melanoma	3.13e-06	1.38e-05	CbGpPWpGaD
